IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 13.1 SEK 8.26% Market Closed
Market Cap: 678.4m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IRLAB Therapeutics AB
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
PP&E Net
kr6.7m
CAGR 3-Years
16%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
PP&E Net
kr59.4m
CAGR 3-Years
89%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
PP&E Net
kr40.2m
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
PP&E Net
kr522.4m
CAGR 3-Years
118%
CAGR 5-Years
100%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
PP&E Net
kr4.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
PP&E Net
kr1.1m
CAGR 3-Years
-24%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
679.5m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
16.06 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is IRLAB Therapeutics AB's PP&E Net?
PP&E Net
6.7m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's PP&E Net amounts to 6.7m SEK.

What is IRLAB Therapeutics AB's PP&E Net growth rate?
PP&E Net CAGR 5Y
41%

Over the last year, the PP&E Net growth was -17%. The average annual PP&E Net growth rates for IRLAB Therapeutics AB have been 16% over the past three years , 41% over the past five years .

Back to Top